{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:31:01Z","timestamp":1793255461638,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["2040 RD21\/0005\/0021"],"award-info":[{"award-number":["2040 RD21\/0005\/0021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.trre.2024.100856","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T11:39:30Z","timestamp":1714563570000},"page":"100856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Laia","family":"Oliveras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Fav\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manonelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Couceiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Melilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2024.100856_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/tri.13783","article-title":"Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics","volume":"34","author":"Hecking","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e3182584831","article-title":"Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation","volume":"94","author":"Wauters","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0015","series-title":"Immunosuppression and post-transplant hyperglycemia","volume":"Vol 11","author":"Montero","year":"2015"},{"key":"10.1016\/j.trre.2024.100856_bb0020","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.kint.2019.06.026","article-title":"Prediabetes is a risk factor for cardiovascular disease following renal transplantation","volume":"96","author":"Porrini","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100856_bb0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000514288","article-title":"Post-transplant diabetes mellitus and prediabetes in renal transplant recipients: an update","volume":"145","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.trre.2024.100856_bb0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/ndt\/gfac291","article-title":"Post-transplant diabetes mellitus and renal cell cancer after renal transplantation","volume":"38","author":"Porrini","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ndt\/gfv368","article-title":"Clinical evolution of post-transplant diabetes mellitus","volume":"31","author":"Porrini","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0040","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes","volume":"45","author":"American Diabetes Association pProfessional pPractice cCommittee","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2024.100856_bb0045","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100856_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100856_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100856_bb0060","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine a in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1399-0012.2009.01127.x","article-title":"A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin\u00ae in living-donor kidney transplantation","volume":"24","author":"Woodle","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.TP.0000441089.39840.66","article-title":"Randomized trial of three induction antibodies in kidney transplantation: long-term results","volume":"97","author":"Ciancio","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0075","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/TP.0b013e3182384b21","article-title":"Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation","volume":"92","author":"Ciancio","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ekir.2021.11.028","article-title":"A randomized controlled trial on safety of steroid avoidance in immunologically low-risk kidney transplant recipients","volume":"7","author":"Ekberg","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trre.2024.100856_bb0085","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100856_bb0090","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0095","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.transproceed.2008.07.085","article-title":"Campath-1H (Alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up","volume":"40","author":"Mu\u00f1oz","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0100","series-title":"Canadian multicentre trial of tacrolimus\/azathioprine\/steroids versus tacrolimus\/mycophenolate mofetil\/steroids versus neoral\/mycophenolate mofetil\/steroids in renal transplantation","author":"Busque","year":"2001"},{"key":"10.1016\/j.trre.2024.100856_bb0105","series-title":"Transplantation proceedings","first-page":"87","article-title":"Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function","volume":"vol. 35","author":"Liu","year":"2003"},{"key":"10.1016\/j.trre.2024.100856_bb0110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study","volume":"359","author":"Margreiter","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100856_bb0115","series-title":"Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression","volume":"Vol. 13","author":"Van Duijnhoven","year":"2002"},{"key":"10.1016\/j.trre.2024.100856_bb0120","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0125","series-title":"One-year follow-up of a brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation","author":"Campos","year":"2002"},{"key":"10.1016\/j.trre.2024.100856_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.TP.0000162980.68628.5A","article-title":"A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients","volume":"80","author":"Hardinger","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1432-2277.2004.00055.x","article-title":"Long-term results of a prospective randomized trial comparing tacrolimus versus cyclosporine in African-American recipients of primary cadaver renal transplant","volume":"18","author":"Jarzembowski","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0140","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.TP.0000437669.93963.8E","article-title":"Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"97","author":"Silva","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0145","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ekir.2018.07.009","article-title":"Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of Posttransplant diabetes mellitus","volume":"3","author":"Torres","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trre.2024.100856_bb0150","series-title":"Tacrolimus\/\u201clow-dose\u201d mycophenolate Mofetil versus microemulsion cyclosporine\/\u201clow-dose\u201d mycophenolate Mofetil after kidney Transplantation-1-year follow-up of a prospective","author":"Yang","year":"1999"},{"key":"10.1016\/j.trre.2024.100856_bb0155","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/01.TP.0000069831.76067.22","article-title":"Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1432-2277.2009.00955.x","article-title":"Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up","volume":"23","author":"Lee","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0165","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0041-1345(98)00248-6","article-title":"Prospective randomized study comparing FK 506 (Prograf) and cyclosporine a (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases","volume":"30","author":"Morris-Stiff","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0170","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1432-2277.2006.00335.x","article-title":"Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients","volume":"19","author":"Cheung","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0175","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00007890-200003150-00028","article-title":"Randomized trial of tacrolimus (prograf) in combination with azathioprine or mychophenolate mofetil versus cyclosporine (neoral) with mycophhenolate mofetil after cadaveric kidney transplantation","author":"Johnson","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0180","first-page":"809","article-title":"Phase II FK 506 multicenter concentration control study: one-year follow-up","volume":"27","author":"Laskow","year":"1995","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0185","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9610(99)00042-2","article-title":"A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants","volume":"177","author":"Raofi","year":"1999","journal-title":"Am J Surg"},{"key":"10.1016\/j.trre.2024.100856_bb0195","first-page":"3065","article-title":"FK 506 in clinical kidney transplantation","volume":"6","author":"Shapiro","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0200","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0205","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0041-1345(00)01405-6","article-title":"Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation","volume":"32","author":"Yu","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0210","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to Calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100856_bb0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"Osaka trial: a randomized, controlled trial comparing tacrolimus qd and bd in kidney transplantation","volume":"96","author":"Albano","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0220","article-title":"Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: a prospective randomized","volume":"29","author":"Adel Bakr","year":"2018","journal-title":"Trial"},{"key":"10.1016\/j.trre.2024.100856_bb0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2015.10.024","article-title":"Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial","volume":"67","author":"Rostaing","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100856_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/941640","article-title":"Renal function and NODM in De novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC-MPS","volume":"2012","author":"Chan","year":"2012","journal-title":"J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0235","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.transproceed.2007.03.014","article-title":"Low-dose versus high-dose cyclosporine induction protocols in renal transplantation","volume":"39","author":"Ghafari","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0240","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0012.2009.00962.x","article-title":"Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation","volume":"23","author":"\u00c5sberg","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0245","series-title":"Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients","volume":"Vol. 40","author":"Garcia","year":"2007"},{"key":"10.1016\/j.trre.2024.100856_bb0250","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0255","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10157-008-0077-y","article-title":"Long-term graft outcome in patients with chronic allograft nephropathy after immunosuppression modifications","volume":"13","author":"El-Agroudy","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0260","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/ndt\/gfl397","article-title":"Conversion of ciclosporin a to tacrolimus in kidney transplant recipients with chronic allograft nephropathy","volume":"21","author":"Tang","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0265","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/TP.0b013e31816b4388","article-title":"Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF study","volume":"85","author":"Shihab","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0270","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2011010006","article-title":"Randomized trial of immunosuppressive regimens in renal transplantation","volume":"22","author":"Guerra","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0275","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.transproceed.2016.03.048","article-title":"Pilot randomized trial of tacrolimus\/Everolimus vs tacrolimus\/enteric-coated mycophenolate sodium in adult, primary kidney transplant recipients at a single center","volume":"48","author":"Ciancio","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0280","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - an interim analysis","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0285","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0290","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of Everolimus plus low-dose tacrolimus versus mycophenolate Mofetil plus standard-dose tacrolimus in De novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0295","article-title":"Open-label, randomized study of transition from tacrolimus to Sirolimus immunosuppression in renal allograft recipients. Transplant","volume":"2","author":"Tedesco-Silva","year":"2016","journal-title":"Direct"},{"key":"10.1016\/j.trre.2024.100856_bb0300","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.transproceed.2010.02.083","article-title":"Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in De novo renal allograft patients receiving Sirolimus","volume":"42","author":"Tedesco-Silva","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0305","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced Calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0310","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different Dosagesof Sirolimus in kidney transplantation: results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/731426","article-title":"Comparable renal function at 6 months with tacrolimus combined with fixed-dose Sirolimus or MMF: results of a randomized multicenter trial in renal transplantation","volume":"2010","author":"Van Gurp","year":"2010","journal-title":"J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0320","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"10.1016\/j.trre.2024.100856_bb0325","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","article-title":"Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen","volume":"22","author":"Sampaio","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0330","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfx093","article-title":"De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial","volume":"32","author":"Huh","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0335","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/TP.0b013e318242be28","article-title":"Effect of Everolimus on left ventricular hypertrophy of De novo kidney transplant recipients","volume":"93","author":"Paoletti","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0340","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1590\/S0100-879X2004000900004","article-title":"Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine","volume":"37","author":"Machado","year":"2004","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.trre.2024.100856_bb0345","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with Sirolimus or mycophenolate Mofetil in kidney transplantation: results at 1 year","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0355","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1600-6143.2006.01340.x","article-title":"Long-term renal allograft function on a tacrolimus-based, Pred-free maintenance immunosuppression comparing Sirolimus vs. MMF","volume":"6","author":"Gallon","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0360","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12141","article-title":"Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial","volume":"27","author":"Favi","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100856_bb0370","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes","volume":"20","author":"Anil Kumar","year":"2008","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2024.100856_bb0375","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin\u00ae, mycophenolate Mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0380","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/j.1600-6143.2005.01107.x","article-title":"Influence of co-medication with Sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation","volume":"5","author":"Cattaneo","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0385","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate Mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0390","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0395","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0400","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without Calcineurin inhibitors: initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0405","article-title":"Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients","volume":"0","author":"Pescovitz","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2024.100856_bb0410","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0415","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0041-1345(03)00226-4","article-title":"Kidney transplantation without calcineurin inhibitors using sirolimus","volume":"35","author":"Stegall","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0420","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of Calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0425","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.tp.0000173378.28790.0b","article-title":"Comparison of steroid avoidance in tacrolimus\/mycophenolate Mofetil and tacrolimus\/Sirolimus combination in kidney transplantation monitored by surveillance biopsy","volume":"80","author":"Anil Kumar","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0430","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/tri.12862","article-title":"Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation","volume":"29","author":"Cruzado","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0435","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled spare-the-nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100856_bb0440","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","article-title":"Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients","volume":"16","author":"Stallone","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0445","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from Calcineurin inhibitor therapy to Everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0450","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/tri.13798","article-title":"5-year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients","volume":"34","author":"Pipeleers","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0455","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/ajt.14619","article-title":"Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C study) \u2013 results of a randomized controlled clinical trial","volume":"18","author":"Haynes","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0460","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1111\/ajt.12437","article-title":"Impact of Calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen","volume":"13","author":"Chhabra","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0465","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100856_bb0470","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/ajt.14048","article-title":"Early conversion to Prednisolone\/Everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial","volume":"17","author":"Bemelman","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0475","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ajt.15081","article-title":"Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: results of a randomized trial","volume":"19","author":"T\u00f6nshoff","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0480","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1111\/ajt.12481","article-title":"Planned randomized conversion from tacrolimus to Sirolimus-based immunosuppressive regimen in De novo kidney transplant recipients","volume":"13","author":"Silva","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0485","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation","volume":"28","author":"Mj\u00f6rnstedt","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0490","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of Sirolimus and mycophenolate Mofetil after short-term Calcineurin inhibitor-based quadruple therapy in De novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0495","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from Calcineurin inhibitor- to Everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222730","article-title":"Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: results of a prospective randomized multicenter study (SENATOR)","volume":"14","author":"Brakemeier","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.trre.2024.100856_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/AOT.927984","article-title":"Effect of everolimus with low-dose tacrolimus on development of new-onset diabetes after transplantation and allograft function in kidney transplantation: a multicenter, open-label, randomized trial","volume":"26","author":"Kim","year":"2021","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/tri.12878","article-title":"ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus","volume":"30","author":"Rummo","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100856_bb0515","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0520","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0525","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0530","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0535","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","article-title":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0540","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0545","first-page":"13","article-title":"Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients","author":"Tawhari","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100856_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100574","article-title":"Cardiovascular risk following conversion to Belatacept from a Calcineurin inhibitor in kidney transplant recipients: a randomized clinical trial","volume":"5","author":"Bredewold","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.trre.2024.100856_bb0555","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.transproceed.2015.12.013","article-title":"Early steroid withdrawal in recipients of a kidney transplant from a living donor: experience of a single Mexican center","volume":"48","author":"Andrade-Sierra","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0560","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.trre.2024.100856_bb0565","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0041-1345(97)83775-X","article-title":"A randomized study comparing cyclosporine alone vs double and triple therapy in renal transplants","volume":"29","author":"Ponticelli","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0570","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-198704000-00010","article-title":"A controlled trial of steroids in cyclosporine-treated renal transplant recipients","volume":"43","author":"Griffin","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0575","first-page":"673","article-title":"Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study","volume":"5","author":"Nematalla","year":"2007","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0580","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.transproceed.2004.11.033","article-title":"A randomized trial of steroid avoidance in renal transplant patients treated with Everolimus and cyclosporine","volume":"37","author":"Montagnino","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0585","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0590","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1111\/ajt.12866","article-title":"Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study","volume":"14","author":"Cantarovich","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0595","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1097\/01.tp.0000188300.26762.74","article-title":"Two corticosteroid-free regimens\u2014tacrolimus monotherapy after Basiliximab administration and tacrolimus\/mycophenolate Mofetil\u2014in comparison with a standard triple regimen in renal transplantation: results of the atlas study","volume":"80","author":"V\u00edtko","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0600","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000794","article-title":"Early steroid withdrawal compared with standard immunosuppression in kidney transplantation - interim analysis of the Amsterdam-Leiden-Groningen randomized controlled trial","volume":"4","author":"van Sandwijk","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100856_bb0605","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-6143.2004.00638.x","article-title":"Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial","volume":"5","author":"Vanrenterghem","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0610","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0041-1345(02)02983-4","article-title":"Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil","volume":"34","author":"Sola","year":"2002","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0615","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1399-0012.2005.00430.x","article-title":"Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine","volume":"20","author":"Pelletier","year":"2006","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0620","first-page":"121","article-title":"Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine","volume":"20","author":"Maiorca","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0625","first-page":"990","article-title":"Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients","volume":"23","author":"Gulanikar","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100856_bb0630","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/00007890-199611270-00008","article-title":"In vitro sensitivity to prednisolone may predict kidney rejection after steroid withdrawal","volume":"62","author":"Bouma","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0635","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"2017","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2024.100856_bb0640","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0645","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000964","article-title":"Late conversion from Calcineurin inhibitors to Belatacept in kidney-transplant recipients has a significant beneficial impact on glycemic parameters","author":"Terrec","year":"2020","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100856_bb0650","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/ajt.14323","article-title":"Deciphering tacrolimus-induced toxicity in pancreatic \u03b2 cells","volume":"17","author":"Tri\u00f1anes","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0655","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/db19-0828","article-title":"Tacrolimus-induced BMP\/SMAD signaling associates with metabolic stress-activated FOXO1 to trigger \u03b2-cell failure","volume":"69","author":"Tri\u00f1anes","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2024.100856_bb0660","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/biom12050614","article-title":"Roles of mTOR in the regulation of pancreatic \u03b2-cell mass and insulin secretion","volume":"12","author":"Sichiro","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.trre.2024.100856_bb0665","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic \u03b2-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2024.100856_bb0670","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00125-012-2475-7","article-title":"Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)","volume":"55","author":"Barlow","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.trre.2024.100856_bb0675","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007890-200202150-00007","article-title":"Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and wistar rat islets","volume":"73","author":"Paty","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100856_bb0680","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/j.1476-5381.2011.01716.x","article-title":"Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats","volume":"165","author":"Deblon","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.trre.2024.100856_bb0685","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1681\/ASN.2006030196","article-title":"Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation","volume":"17","author":"Di Paolo","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100856_bb0690","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0695","article-title":"Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants","volume":"4","author":"Kumar","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.trre.2024.100856_bb0700","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.trre.2024.100856_bb0705","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfr374","article-title":"Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review","volume":"27","author":"Pascual","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100856_bb0710","article-title":"Effect of early steroid withdrawal on Posttransplant diabetes among kidney transplant recipients differs by recipient age","volume":"8","author":"Ahn","year":"2021","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100856_bb0715","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients","volume":"2016","author":"Haller","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:25:26Z","timestamp":1778563526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X24000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0955470X24000399"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2024.100856","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2024.100856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100856"}}